Sign in or create an account to add this stock to your watchlist.
About AVEO Pharmaceuticals (NASDAQ:AVEO)
AVEO Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes a portfolio of targeted medicines for oncology and other areas of unmet medical need. It markets its lead candidate, tivozanib, an oral, once-daily, vascular endothelial growth factor receptor tyrosine kinase inhibitor, which is used for the treatment of renal cell carcinoma (RCC). The company has also completed a Phase 3 TIVO-3 trial of tivozanib for the treatment of advanced RCC; and initiated enrollment in a phase Ib/II clinical trial of tivozanib in combination with Opdivo (nivolumab), an immune checkpoint (PD-1) inhibitor, for the treatment of advanced RCC. In addition, it is developing Ficlatuzumab, a potent hepatocyte growth factor inhibitory antibody, in Phase I and Phase II clinical trials in squamous cell carcinoma of the head and neck, metastatic pancreatic ductal cancer, and acute myeloid leukemia; and AV-203, a potent anti-ErbB3 specific monoclonal antibody, which has completed Phase I clinical trial for treating esophageal cancer. The company's preclinical stage products include AV-380, a potent humanized IgG1 inhibitory monoclonal antibody for the treatment or prevention of cachexia; and AV-353 for the treatment of pulmonary arterial hypertension. It has strategic partnerships with CANbridge Life Sciences Ltd.; EUSA Pharma (UK) Limited; Novartis International Pharmaceutical Ltd.; Biodesix, Inc.; St. Vincent's Hospital Sydney Limited; Biogen Idec; and Kyowa Hakko Kirin Co., Ltd. The company was formerly known as GenPath Pharmaceuticals, Inc. and changed its name to AVEO Pharmaceuticals, Inc. in March 2005. AVEO Pharmaceuticals, Inc. was incorporated in 2001 and is based in Cambridge, Massachusetts.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:AVEO
CUSIP05358810
Phone617-588-1960
Debt
Debt-to-Equity Ratio-0.36
Current Ratio1.34
Quick Ratio1.34
Price-To-Earnings
Trailing P/E Ratio-14.63
Forward P/E Ratio-8.67
P/E GrowthN/A
Sales & Book Value
Annual Sales$7.58 million
Price / Sales36.70
Cash FlowN/A
Price / CashN/A
Book Value($0.34) per share
Price / Book-6.88
Profitability
EPS (Most Recent Fiscal Year)($0.16)
Net Income$-65,020,000.00
Net Margins-1,073.16%
Return on EquityN/A
Return on Assets-39.88%
Miscellaneous
Employees19
Outstanding Shares118,870,000
AVEO Pharmaceuticals (NASDAQ:AVEO) Frequently Asked Questions
What is AVEO Pharmaceuticals' stock symbol?
AVEO Pharmaceuticals trades on the NASDAQ under the ticker symbol "AVEO."
How were AVEO Pharmaceuticals' earnings last quarter?
AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) posted its quarterly earnings data on Tuesday, May, 8th. The biopharmaceutical company reported ($0.08) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.07) by $0.00. The biopharmaceutical company had revenue of $1.03 million for the quarter, compared to analysts' expectations of $0.98 million. View AVEO Pharmaceuticals' Earnings History.
What price target have analysts set for AVEO?
4 Wall Street analysts have issued 1 year target prices for AVEO Pharmaceuticals' shares. Their predictions range from $3.00 to $5.00. On average, they expect AVEO Pharmaceuticals' stock price to reach $4.1667 in the next year. View Analyst Ratings for AVEO Pharmaceuticals.
Are investors shorting AVEO Pharmaceuticals?
AVEO Pharmaceuticals saw a increase in short interest in the month of April. As of April 30th, there was short interest totalling 9,843,720 shares, an increase of 17.0% from the April 13th total of 8,416,656 shares. Based on an average trading volume of 1,255,958 shares, the short-interest ratio is presently 7.8 days. Currently, 10.3% of the shares of the stock are short sold.
Who are some of AVEO Pharmaceuticals' key competitors?
Some companies that are related to AVEO Pharmaceuticals include Zai Lab (ZLAB), Endocyte (ECYT), Karyopharm Therapeutics (KPTI), Omeros (OMER), Eagle Pharmaceuticals (EGRX), CytomX Therapeutics (CTMX), Amarin (AMRN), MacroGenics (MGNX), OptiNose (OPTN), UroGen Pharma (URGN), Abeona Therapeutics (ABEO), Vanda Pharmaceuticals (VNDA), Arrowhead Pharmaceuticals (ARWR), Adamas Pharmaceuticals (ADMS) and Assembly Biosciences (ASMB).
Who are AVEO Pharmaceuticals' key executives?
AVEO Pharmaceuticals' management team includes the folowing people:
- Mr. Michael P. Bailey, CEO, Pres & Director (Age 53)
- Dr. Michael N. Needle M.D., Chief Medical Officer (Age 58)
- Mr. Matthew D. Dallas, Chief Financial Officer (Age 43)
- Dr. Emile Farhan Ph.D., VP of Technical Operations
- Ms. Karuna Rubin J.D., VP of Legal Affairs and Corp. Sec.
Has AVEO Pharmaceuticals been receiving favorable news coverage?
Media coverage about AVEO stock has trended somewhat positive recently, according to Accern Sentiment. The research firm scores the sentiment of news coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. AVEO Pharmaceuticals earned a daily sentiment score of 0.15 on Accern's scale. They also gave media stories about the biopharmaceutical company an impact score of 46.62 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company's share price in the immediate future.
Who are AVEO Pharmaceuticals' major shareholders?
AVEO Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional investors include venBio Select Advisor LLC (2.72%), Point72 Asset Management L.P. (0.79%), Tibra Equities Europe Ltd (0.22%), X Square Capital LLC (0.19%), Spark Investment Management LLC (0.14%) and Element Capital Management LLC (0.11%). Company insiders that own AVEO Pharmaceuticals stock include Equity Opportunities Iv Growth, Peter J Barris and Ravi Viswanathan. View Institutional Ownership Trends for AVEO Pharmaceuticals.
Which major investors are selling AVEO Pharmaceuticals stock?
Which major investors are buying AVEO Pharmaceuticals stock?
AVEO stock was acquired by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Tibra Equities Europe Ltd, Element Capital Management LLC, Birchview Capital LP, Verition Fund Management LLC and X Square Capital LLC. Company insiders that have bought AVEO Pharmaceuticals stock in the last two years include Equity Opportunities Iv Growth, Peter J Barris and Ravi Viswanathan. View Insider Buying and Selling for AVEO Pharmaceuticals.
How do I buy shares of AVEO Pharmaceuticals?
Shares of AVEO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is AVEO Pharmaceuticals' stock price today?
One share of AVEO stock can currently be purchased for approximately $2.34.
How big of a company is AVEO Pharmaceuticals?
AVEO Pharmaceuticals has a market capitalization of $256.75 million and generates $7.58 million in revenue each year. The biopharmaceutical company earns $-65,020,000.00 in net income (profit) each year or ($0.16) on an earnings per share basis. AVEO Pharmaceuticals employs 19 workers across the globe.
How can I contact AVEO Pharmaceuticals?
AVEO Pharmaceuticals' mailing address is ONE BROADWAY 14TH FLOOR, CAMBRIDGE MA, 02142. The biopharmaceutical company can be reached via phone at 617-588-1960 or via email at [email protected]
MarketBeat Community Rating for AVEO Pharmaceuticals (AVEO)
MarketBeat's community ratings are surveys of what our community members think about AVEO Pharmaceuticals and other stocks. Vote "Outperform" if you believe AVEO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AVEO will underperform the S&P 500 over the long term. You may vote once every thirty days.
AVEO Pharmaceuticals (NASDAQ:AVEO) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
4 Wall Street analysts have issued ratings and price targets for AVEO Pharmaceuticals in the last 12 months. Their average twelve-month price target is $4.1667, suggesting that the stock has a possible upside of 78.06%. The high price target for AVEO is $5.00 and the low price target for AVEO is $3.00. There are currently 4 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 3.00 | 3.00 | 3.00 | 3.00 |
| Ratings Breakdown: | 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $4.1667 | $4.1667 | $4.1667 | $4.1667 |
| Price Target Upside: | 78.06% upside | 34.41% upside | 34.41% upside | 37.97% upside |
AVEO Pharmaceuticals (NASDAQ:AVEO) Consensus Price Target History
AVEO Pharmaceuticals (NASDAQ:AVEO) Analyst Ratings History
Show:
(Data available from 5/23/2016 forward)
AVEO Pharmaceuticals (NASDAQ:AVEO) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
AVEO Pharmaceuticals (NASDAQ AVEO) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 4.40%
Institutional Ownership Percentage: 50.23%
AVEO Pharmaceuticals (NASDAQ AVEO) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 5/21/2018 | Equity Opportunities Iv Growth | Major Shareholder | Buy | 236,479 | $2.13 | $503,700.27 | |  |
| 5/17/2018 | Ravi Viswanathan | Major Shareholder | Buy | 184,179 | $2.13 | $392,301.27 | | |
| 5/8/2018 | Ravi Viswanathan | Major Shareholder | Buy | 70,873 | $2.13 | $150,959.49 | | |
| 4/10/2018 | Peter J Barris | Major Shareholder | Buy | 920,976 | $2.30 | $2,118,244.80 | | |
| 4/6/2018 | Ravi Viswanathan | Major Shareholder | Buy | 685,676 | $2.24 | $1,535,914.24 | | |
| 3/28/2017 | Equity Opportunities Iv Growth | Major Shareholder | Buy | 6,000,000 | $0.50 | $3,000,000.00 | | |
| 1/16/2015 | Matthew D Dallas | VP | Sell | 3,075 | $0.82 | $2,521.50 | | |
| 1/7/2015 | Michael P Bailey | CEO | Sell | 4,484 | $0.80 | $3,587.20 | | |
| 1/30/2014 | Joseph Vittiglio | SVP | Sell | 5,430 | $1.64 | $8,905.20 | 34,121 | |
| 3/14/2013 | David Brannon Johnston | CFO | Sell | 1,061 | $7.34 | $7,787.74 | | |
| 3/7/2013 | Henri A Termeer | Director | Buy | 55,499 | $6.73 | $373,508.27 | | |
| 12/13/2012 | Ngoc Tuan Ha | CEO | Buy | 75,000 | $6.65 | $498,750.00 | | |
| 12/13/2012 | Robert C Young | Director | Buy | 2,371 | $6.78 | $16,075.38 | | |
| 12/3/2012 | Robert C Young | Director | Buy | 1,250 | $6.41 | $8,012.50 | | |
| 9/13/2012 | David Brannon Johnston | CFO | Sell | 1,386 | $10.60 | $14,691.60 | | |
| 8/8/2012 | Robert C Young | Director | Buy | 1,000 | $8.63 | $8,630.00 | | |
(Data available from 1/1/2013 forward)
AVEO Pharmaceuticals (NASDAQ AVEO) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Equity Opportunities Iv Growth Purchases 236,479 Shares of AVEO Pharmaceuticals, Inc. (AVEO) Stock
www.americanbankingnews.com - May 21 at 7:34 PM |
| AVEO Pharmaceuticals, Inc. (AVEO) Major Shareholder Buys $392,301.27 in Stock
www.americanbankingnews.com - May 21 at 7:34 PM |
| AVEO Pharmaceuticals Inc. (AVEO) Receives Average Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - May 19 at 1:34 AM |
 | Audentes Therapeutics and Three More Stocks Under Scanner in the Biotech Space
finance.yahoo.com - May 18 at 8:39 AM |
| AVEO Pharmaceuticals (AVEO) Downgraded by BidaskClub
www.americanbankingnews.com - May 15 at 1:21 PM |
| Seaport Global Securities Analysts Boost Earnings Estimates for AVEO Pharmaceuticals Inc. (AVEO)
www.americanbankingnews.com - May 14 at 2:48 AM |
| AVEO Pharmaceuticals Inc. (AVEO) Sees Large Growth in Short Interest
www.americanbankingnews.com - May 12 at 1:06 AM |
| FY2018 EPS Estimates for AVEO Pharmaceuticals Inc. (AVEO) Decreased by Analyst
www.americanbankingnews.com - May 11 at 11:05 AM |
| Insider Buying: AVEO Pharmaceuticals Inc. (AVEO) Major Shareholder Acquires 70,873 Shares of Stock
www.americanbankingnews.com - May 10 at 8:26 PM |
| AVEO Pharmaceuticals (AVEO) Releases Quarterly Earnings Results, Misses Expectations By $0.01 EPS
www.americanbankingnews.com - May 10 at 6:12 PM |
| Q3 2018 EPS Estimates for AVEO Pharmaceuticals Inc. (AVEO) Raised by Analyst
www.americanbankingnews.com - May 10 at 7:55 AM |
| AVEO Pharmaceuticals (AVEO) Q1 Loss Wider Than Expected
finance.yahoo.com - May 9 at 5:34 PM |
 | Here's Why AVEO Oncology Fell as Much as 17% Today
www.msn.com - May 8 at 5:39 PM |
| Here's Why AVEO Pharmaceuticals Fell as Much as 17% Today
finance.yahoo.com - May 8 at 5:39 PM |
 | Here's Why AVEO Pharmaceuticals Fell as Much as 17% Today
www.fool.com - May 8 at 2:40 PM |
 | AVEO Pharmaceuticals misses by $0.01, misses on revenue
seekingalpha.com - May 8 at 8:16 AM |
| AVEO Pharmaceuticals Inc. (AVEO) Expected to Post Quarterly Sales of $980,000.00
www.americanbankingnews.com - May 8 at 3:36 AM |
| AVEO Pharmaceuticals Inc. (AVEO) Expected to Announce Earnings of -$0.07 Per Share
www.americanbankingnews.com - May 6 at 10:12 AM |
| AVEO Pharmaceuticals (AVEO) Rating Increased to Hold at Zacks Investment Research
www.americanbankingnews.com - May 5 at 1:09 AM |
| AVEO Pharmaceuticals Inc. Forecasted to Earn Q1 2018 Earnings of ($0.08) Per Share (AVEO)
www.americanbankingnews.com - May 4 at 5:48 AM |
| AVEO Pharmaceuticals (AVEO) Upgraded to Buy by ValuEngine
www.americanbankingnews.com - May 4 at 12:20 AM |
| AVEO Pharmaceuticals Inc. Expected to Post Q2 2018 Earnings of ($0.07) Per Share (AVEO)
www.americanbankingnews.com - May 3 at 9:01 AM |
 | AVEO Pharmaceuticals (AVEO) Q1 Earnings: What's in Store?
www.zacks.com - April 30 at 8:24 AM |
| AVEO Pharmaceuticals Inc. (AVEO) Short Interest Update
www.americanbankingnews.com - April 27 at 1:24 AM |
| AVEO Pharmaceuticals Inc. (AVEO) Given Average Rating of "Hold" by Analysts
www.americanbankingnews.com - April 24 at 1:30 AM |
 | Ex-Aveo Pharmaceuticals CFO must face SEC trial, judge rules
www.reuters.com - April 21 at 8:19 AM |
| SEC seeks to block ex-Aveo CFO's testimony about consulting counsel
www.reuters.com - April 19 at 8:16 AM |
| AVEO Pharmaceuticals (AVEO) Upgraded to "Buy" at Zacks Investment Research
www.americanbankingnews.com - April 16 at 9:17 PM |
| AVEO Down 7.7% Since Earnings Report: Can It Rebound?
finance.yahoo.com - April 12 at 5:39 PM |
| AVEO Pharmaceuticals (AVEO) Presents At H. C. Wainwright Global Life Sciences Conference - Slideshow
seekingalpha.com - April 11 at 5:32 PM |
| AVEO Pharmaceuticals' (AVEO) Buy Rating Reiterated at Piper Jaffray
www.americanbankingnews.com - April 10 at 10:31 PM |
| Insider Buying: AVEO Pharmaceuticals, Inc. (AVEO) Major Shareholder Acquires 685,676 Shares of Stock
www.americanbankingnews.com - April 10 at 7:30 PM |
| Peter J. Barris Purchases 920,976 Shares of AVEO Pharmaceuticals, Inc. (AVEO) Stock
www.americanbankingnews.com - April 10 at 7:12 PM |
| Why AVEO Oncology Jumped Higher Today
finance.yahoo.com - April 9 at 5:22 PM |
| Moving Average Crossover Alert: AVEO Pharmaceuticals, Inc. (AVEO)
finance.yahoo.com - April 5 at 10:10 AM |
| Zacks: Brokerages Anticipate AVEO Pharmaceuticals, Inc. (AVEO) to Post -$0.07 EPS
www.americanbankingnews.com - April 2 at 9:12 AM |
| AVEO Pharmaceuticals, Inc. (AVEO) Receives Average Rating of "Hold" from Analysts
www.americanbankingnews.com - March 30 at 1:34 AM |
| AVEO Pharmaceuticals (AVEO) Lifted to Hold at Zacks Investment Research
www.americanbankingnews.com - March 29 at 11:18 PM |
| AVEO Pharmaceuticals (AVEO) Presents At Needham And Company 17th Annual Healthcare Conference - Slideshow
seekingalpha.com - March 29 at 5:30 PM |
| AVEO Pharmaceuticals (AVEO) Rating Reiterated by B. Riley
www.americanbankingnews.com - March 28 at 12:58 PM |
| AVEO Pharmaceuticals (AVEO) Upgraded to "Sell" by BidaskClub
www.americanbankingnews.com - March 26 at 5:58 PM |
| AVEO Pharmaceuticals (AVEO) Stock Rating Lowered by BidaskClub
www.americanbankingnews.com - March 25 at 12:52 AM |
| AVEO Pharmaceuticals (AVEO) Rating Increased to Sell at BidaskClub
www.americanbankingnews.com - March 24 at 10:58 AM |
| Options Traders Expect Huge Moves in AVEO Pharmaceuticals (AVEO) Stock
finance.yahoo.com - March 23 at 5:42 PM |
| AVEO Oncology Announces Publication of Long-term Follow-up Results from TIVO-1 Extension Study (Study 902) in TKI Refractory RCC
finance.yahoo.com - March 21 at 5:38 PM |
| AVEO Pharmaceuticals (AVEO) Q4 Loss Widens, Shares Down - Yahoo Finance
finance.yahoo.com - March 16 at 8:19 AM |
| -$0.06 EPS Expected for AVEO Pharmaceuticals, Inc. (AVEO) This Quarter
www.americanbankingnews.com - March 16 at 7:33 AM |
| Q3 2018 EPS Estimates for AVEO Pharmaceuticals, Inc. Cut by B. Riley (AVEO)
www.americanbankingnews.com - March 15 at 8:15 AM |
| AVEO Pharmaceuticals, Inc. Forecasted to Earn Q1 2019 Earnings of ($0.05) Per Share (AVEO)
www.americanbankingnews.com - March 14 at 12:56 PM |
| BRIEF-Aveo Quarterly Loss Per Share $0.08
www.reuters.com - March 13 at 7:17 PM |
AVEO Pharmaceuticals (NASDAQ:AVEO) SEC Filings
This page is loading this company's SEC Filings. Please wait...
AVEO Pharmaceuticals (NASDAQ:AVEO) Income Statement, Balance Sheet and Cash Flow Statement
AVEO Pharmaceuticals (NASDAQ AVEO) Stock Chart for Wednesday, May, 23, 2018
Loading chart…
